Long-Term Follow-Up in Patients on PCSK9 Inhibitor Therapy: Combining Fast Track Strategy and Outpatient Management
Anno:
2024
BACKGROUND: Dyslipidemia is a significant risk factor for cardiovascular diseases, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as an effective treatment option. This study aims to investigate the lipid profile in the long-term follow-up of dyslipidemic patients receiving PCSK9 inhibitor therapy in an entirely outpatient setting….